NEUVIOR® | GLIO | Research proposal

From treatment survival to durable control.

Editable scientific poster and source companion. Local review draft; publication pending.

GLIO: from treatment survival to durable controlNEUVIOR research proposal poster. External published microscopy, evidence context, planned evaluation and documented design progress. No original experimental results reported.NEUVIOR® | GLIORESEARCH PROPOSAL | OCTOBER 2026From treatment survivalto durable control.Adult glioblastoma, IDH-wildtype. A public-level research framework connectingresidual-cell biology, regrowth, exposure and neural function.THE SCIENTIFIC QUESTIONWhich surviving cells matter?After a defined treatment background, which malignantpopulations cause or support later regrowth - and can a usefulintervention change that contribution without unacceptableneural injury?Published starting pointsCell-state diversity and plasticity make a single universal survivorpopulation an assumption to test (Neftel et al., 2019). GPX4-relatedvulnerability has been shown in specific experimental glioma states(Banu et al., 2024).Separate senolytic work motivates examining supporting-cellcontributions (Tomimatsu et al., 2025). These external results arise indifferent models; their combination has not been validated.The unresolved bridgeTreatment survival and marker expression do not establish causalregrowth control. A fair longitudinal comparison must separate directfounders, supporting cells and transient states.EXTERNAL PUBLISHED MICROSCOPYA state has a context.Figure 1 | Banu et al. (2024), Figure 1F. Representative immunofluorescence in engineeredmurine glioma models; external research, not a NEUVIOR experiment or human tissue image.Original Clu, HA and DAPI channels, labels and both 10 µm scale bars are retained.Complete panel F crop, scaled for layout only. © The Author(s), CC BY 4.0. DOI:10.1038/s44318-024-00176-4. Licence: creativecommons.org/licenses/by/4.0/.PROPOSED EVALUATIONMake the next experiment decisive.Compare a defined treatment background with justified adjunctconditions and a combined approach only if the added step earns itscomplexity. Qualify the model and intended state before interpreting anegative result.Follow malignant-cell identity and regrowth after withdrawal. Assesstarget mechanism using independent approaches, alongside measuredexposure and neural function and recovery. Donors are biological units;repeated wells are nested observations.What changes the decision?Advance: reproducible, useful incremental control with an acceptablefunctional response. Revise: weak model retention, failed controls orimprecise estimates. Stop the tested route: no worthwhile added effector persistent neural impairment at the required exposure.Neuronal Gpx4-loss findings motivate delayed functional assessment;genetic deletion is not a candidate-specific drug-safety estimate(Hambright et al., 2017). Numerical thresholds, model access and studycosts require specialist agreement.Figure 2 | Proposed evidence relationshipsOriginal NEUVIOR concept diagram; no measured values or validated surrogate.IdentityWhich population is present?ContributionDoes it cause or support regrowth?DurabilityWhat remains after withdrawal?Exposure + functionIs the effect compatible with recovery?A common comparison links the questions; failure at one link can redirect the programme. Exposure, model validity and neural response must be interpreted together.DOCUMENTED PROGRESSEvidence synthesis, competing explanations and a decision-study framework are documented. The reviewed 8October programme record reports no original NEUVIOR experimental dataset; the proposed comparison has notrun. Working manuscript: not submitted or peer reviewed.NEXT COLLABORATIONStart with a non-confidential capability enquiry. Agree the question, expertise, access and rights. A confidentialbriefing can follow by agreement where an NDA is appropriate. Public scientific context remains availablewithout one.neuvior.com/research/glioblastoma | Draft for scientific and design reviewPUBLIC-LEVEL PROPOSAL | NO EXPERIMENTAL RESULTS REPORTED

Sources and disclosure

Selected-source synthesis and proposed research, with no original NEUVIOR experimental results reported. Scientific authorship and accountable review remain to be confirmed.

Banu, M.A., Dovas, A., Argenziano, M.G. et al. (2024) A cell state-specific metabolic vulnerability to GPX4-dependent ferroptosis in glioblastoma. The EMBO Journal, 43, pp. 4492-4521.
https://doi.org/10.1038/s44318-024-00176-4

Tomimatsu, N. et al. (2025) Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy. EMBO Molecular Medicine, 17, article 6.
https://doi.org/10.1038/s44321-025-00201-x

Neftel, C. et al. (2019) An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell, 178(4), pp. 835-849.e21.
https://doi.org/10.1016/j.cell.2019.06.024

Hambright, W.S. et al. (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biology, 12, pp. 8-17.
https://doi.org/10.1016/j.redox.2017.01.021

Figure 1: Banu et al. (2024), complete panel F crop, © The Author(s), CC BY 4.0. Proportionally scaled only; scientific signals, colours, labels and scale bars unchanged. Figure 2: original conceptual framework, no measured values.

Begin with a non-confidential research enquiry. A confidential briefing can follow by agreement where an NDA is appropriate.